Design Therapeutics Secures $125 Million in Series B Financing to Advance Pipeline of Genomic Medicines for Nucleotide Repeat Expansion Disorders
Amount Raised
$125 Million
Round Type
Series B
CarlsbadBiotechnologyHealthcareHealth CareTherapeuticsDescription
Design Therapeutics, a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, today announced the successful completion of a $125 million Series B financing, led by Logos Capital. Existing investors Cormorant Asset Management, SR One, Quan Capital and WestRiver Group participated in the round, joined by new investors, including funds and accounts managed by BlackRock, Janus Henderson Investors, RA Capital Management, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., Wellington Management, Avoro Capital Advisors, Vivo Capital, and also including a U.S.-based, healthcare-focused fund and a leading global investment firm.
Who else raised in Healthcare and Therapeutics around the same time
Companies in the same sectors as Design Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.
- DTx Pharma, Inc. raised $100M on March 10, 2021.
- Phio Pharmaceuticals raised $14M on February 16, 2021.
- ISOThrive raised $5.2M on February 5, 2021.
- SAGE Therapeutics raised $650M on January 15, 2021.
- Zevra Therapeutics, Inc. raised $31M on January 13, 2021.
- Werewolf Therapeutics raised $72M on January 7, 2021.
Who to call at Design Therapeutics, Inc., and when
A new round usually means Design Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Design Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Design Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Design Therapeutics, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Design Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansDesign Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.